Post hoc subgroup analysis Improvement in SNOT-22 in patients with or without prior sinus surgery Reduction in SNOT-22 score at Week 16 in the subgroups of patients with or without prior sinus surgery1 A post hoc analysis of a pooled population from NAVIGATE I and NAVIGATE II analyzed improvement in SNOT-22 score in the subgroup … Continued

Post hoc subgroup analysis Improvement in SNOT-22 in patients previously using standard nasal steroids1 Improvements in SNOT-22 scores in the subgroup of patients reporting use of standard nasal steroids prior to study entry1 Mean SNOT-22 scores improved by 21 points at Week 16 in patients taking XHANCE (both the 186 mcg BID dose and the … Continued

Post hoc subgroup analysis CONGESTION/OBSTRUCTION REDUCTION IN PATIENTS PREVIOUSLY USING STANDARD NASAL STEROIDS1,2 Reductions in congestion/obstruction at Week 4 in the subgroup of patients reporting standard nasal steroid use prior to study entry1,2 In a subgroup of patients reporting use of a standard nasal steroid within 30 days of the screening visit1: Patients reported a … Continued

Post hoc subgroup analysis POLYP REDUCTION IN PATIENTS PREVIOUSLY USING STANDARD NASAL STEROIDS1 Reductions in nasal polyp grade at Week 16 in the subgroup of patients reporting standard nasal steroid use prior to study entry1 In a subgroup of patients reporting use of a standard nasal steroid within 30 days of the screening visit1: Patients … Continued

XHANCE trial design & details XHANCE is a corticosteroid indicated for the treatment of nasal polyps in patients 18 years of age or older. XHANCE has been extensively studied in over 1500 patients.1-5 646 patients with bilateral nasal polyps evaluated for efficacy and safety for up to 24 weeks2,3 NAVIGATE I and NAVIGATE II were … Continued